During the forecast period, the tetanus market is expected to grow at a CAGR of 4.3%. The global tetanus market is currently worth USD 1.5 billion. By 2032, the tetanus market is expected to be worth USD 2.29 billion.
Attribute
Detail
Tetanus Market CAGR
4.3%
Tetanus Market 2022
USD 1.5 billion
Tetanus Market 2032
USD 2.29 billion
The tetanus market is expected to grow at an exponential rate during the forecast period, owing to increased R&D practices, increased awareness about disease prevention and treatment, and increased healthcare expenditure.
The high R&D expenditure is a key factor contributing to market growth. A large number of products, including GSK-217744, LVBF-0101, TAK-361S, and others, are currently undergoing clinical trials.
Though the market for tetanus appears to be optimistic in the coming years, side effects associated with treatment, high R&D costs, and stringent regulatory procedures in some key countries may have a negative impact on this industry.
The procurement of tetanus vaccination by UNICEF, WHO, and other government initiatives for tetanus prevention and treatment is expected to drive growth in the global tetanus market. Rising tetanus and diphtheria cases, new products in clinical trials, and increased government vaccination and immunization initiatives are the primary drivers of the tetanus market.
Diphtheria, pertussis (DTaP), and tetanus vaccine segment dominate the tetanus market. Due to growing government initiatives to eradicate these diseases, it is expected to show a similar trend over the forecast period. Diphtheria pertussis (DTaP) and the tetanus vaccine segment are being driven by low vaccine costs, rising tetanus cases, and increased availability in low-resource economies such as Africa. Tetanus market demand is expected to come from developing economies such as MEA and Asia Pacific. The government's emphasis on providing dependable healthcare solutions increased healthcare expenditure, and key innovations driven by some of the industry's key players are expected to contribute to the overall growth of the tetanus market in North America and Europe.
When compared to tetanus vaccines, the demand for tetanus vaccines is found to be limited. As not all manufacturers would have licensed tetanus vaccines in all countries procuring through UNICEF, access to vaccines is expected to be limited due to stringent vaccine regulatory environments and licensing in some countries.
The market for tetanus is fragmented and competitive, with several major players. BB-NCIPD, PT Bio Farma, Biological E, Sanofi, GlaxoSmithKline, Serum Institute of India Pvt. Ltd., Accord Healthcare Inc., and Shantha Biotechniques Pvt. Ltd. are some of the key players in the global tetanus market.
In June 2021 Merck & Co. Inc. and Sanofi collaborated to launch VAXELIS (diphtheria and tetanus vaccine) in the United States. The vaccine was approved by the Food and Drug Administration in 2018. ?
In March 2021, BB NCIPD (Bul Bio), an European manufacturer of vaccines will partner with Stablepharma for developing a thermally secure version of tetanus diphtheria (Td) vaccine with the use of StabevaX formulation along with devices.
Tetanus also known as lockjaw, is an acute disease caused by the bacterium clostridium tetani which are present in the environment and particularly found in the soil of moist and warm areas. It is characterized by convulsive spasms and generalized rigidity of the skeletal muscles.
The muscles stiffness is found to be occurred in the jaw and neck first and then become generalized. During the early 1920’s a method for inactivating tetanus by the use of formaldehyde was introduced by Ramon, which led to the development of tetanus toxoid in 1924.
Tetanus following injuries in children and adult may constitute a considerable public health problem. The mortality of tetanus can be 100% if it is not treated. The infection can be treated through vaccination and other medication treatment.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Tetanus Market: Drivers & Restraints
The Tetanus market is expected to grow exponentially during the forecast period, primarily due to the rise in research and development practices, increased awareness about the disease prevention and treatment, and increased healthcare expenditure.
The high expenditure in R&D is the key factor contributing in the growth of global tetanus market. The large number of products such as GSK-217744, LVBF-0101, TAK-361S and others are undergoing the clinical trials currently.
Though the market seems optimistic in coming years, side effects associated with the treatment, high costs of R&D, along with stringent regulatory procedures in some of the key nations can led to some negative impact on this industry.
The procurement of tetanus vaccination by the UNICEF, WHO and other government initiatives for the prevention and treatment of tetanus are expected to create the growth opportunities for the global tetanus market.
Tetanus Market: Overview
It is mandatory that the children younger than 7 years of age should get either DTaP or pediatric DT. The Persons of age 7 or older should get the adult formulation known as adult Td, even if the series of DTaP or pediatric DT is not completed.
Usually, Tetanus toxoid is administered in combination with diphtheria toxoid, as the boosting is required for both antigens periodically. Thus, the market for tetanus toxoid and diphtheria toxoid are expected to enhance the overall growth of tetanus market.
The FDA has approved two brands of Tdap: Boostrix which is approved for persons of 10 years of age and older and Adacel which is approved for persons of 10 through 64 years of age. DTaP and Tdap vaccines do not contain thimerosal as a preservative.
Find your sweet spots for generating winning opportunities in this market.
Tetanus Market: Region-wise Outlook
Demand for tetanus market is expected to generate from developing economies including MEA and Asia Pacific. The government focus towards providing reliable healthcare solution, increasing healthcare expenditure and key innovations driven by some of the key industry leaders are expected to contribute in the overall growth of tetanus market in North America and Europe.
The demand of Td vaccine is found to be limited as compared to that of TT vaccines. The stringent vaccine regulatory environments and licensing in some countries are expected limit access to vaccines, as not all the manufacturers would have licensed Td vaccines in all countries procuring through UNICEF.
Tetanus Market: Key Players
Some of the key market players of global tetanus are BB-NCIPD, PT Bio Farma, Biological E, Sanofi, GlaxoSmithKline, Serum Institute of India Pvt. Ltd., Accord Healthcare Inc., Shanha Biotechniques Pvt Ltd,
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
The report covers exhaustive analysis on
Market Segments
Market Dynamics
Market Size
Current Trends/Issues/Challenges
Competition & Companies involved
Value Chain
Regional analysis includes
North America (U.S., Canada)
Latin America (Mexico. Brazil)
Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
Eastern Europe (Poland, Russia)
Asia Pacific (China, India, ASEAN, Australia & New Zealand)
Japan
Middle East and Africa (GCC, S. Africa, N. Africa)
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Tetanus Market: Segmentation
The Tetanus market is classified on the basis of product type, end user, and geography.
Based on product type, the tetanus market is segmented into the following:
